Inve US ▾
YCYCBD

cbdMD (YCBD) Q3 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q3 FY26)· Health Care· Aug 13, 2026

Source: earnings call transcript

Executive summary

cbdMD, Inc. Q3 FY26 — Top-line Growth Amidst Regulatory Headwinds and Strategic Investments

cbdMD achieved significant top-line growth in Q3 FY26, driven by its wholesale channel and the Bluebird acquisition, despite a challenging regulatory landscape. The company made strategic investments and incurred one-time costs, leading to a wider operating loss, but adjusted EBITDA narrowed. Management is proactively addressing regulatory uncertainty with new product launches and cost reductions, aiming for improved profitability and market share in a dynamic environment.

Highlights

5
  • Net sales grew 20% year-over-year to $5.6 million in Q3 FY26.

  • Wholesale channel sales increased 61% year-over-year, now representing 30% of total sales.

  • Bluebird Botanicals contributed over $500,000 in revenue in its first full quarter post-acquisition.

  • Oasis brand depletions hit a record in July, up 35% over Q3 average, with August on pace to more than double.

  • Implemented a cost reduction program targeting $100,000 to $150,000 in monthly cash savings starting Q4 FY26.

Concerns

5
  • Operating loss widened to $1.1 million in Q3 FY26 from $905,000 in prior year due to deliberate investments and one-time costs.

  • Gross margin declined to 54.7% in Q3 FY26 from 61.5% in prior year due to wholesale shift and higher warehouse labor.

  • Incurred $187,000 increase in inventory reserves in Q3 FY26 due to pending regulatory changes.

  • Incurred $200,000 of additional professional fees in Q3 FY26 for M&A, GRAS report, and other activities.

  • State-level shipping restrictions impacted $150,000 of direct-to-consumer revenue in Q3 FY26.

Guidance & targets

CategoryTargetConfidence
Monthly cost savings
$100,000 to $150,000
high materiality
High
Annualized cost savings
$1.2 million to $1.8 million
high materiality
High
Quarterly revenue for cash flow break-even
low six millions to mid six millions
high materiality
Medium

Segment performance

SegmentRevenueYoYQoQMargin
Wholesale Channel
Led overall revenue growth, reflecting continued momentum and distribution expansion.
Sales increase: $629,000Percentage of total sales: 30% (Q3 FY26)Percentage of total sales: 22% (Q3 FY25)Percentage of total sales (9M FY26): 30%Percentage of total sales (9M FY25): 23%
—61%—lower margins
Direct-to-Consumer
Revenues impacted by state-level shipping restrictions and label changes.
Impacted by state-level shipping restrictions: $150,000
————

Product announcements

ProductTypeDetails
Zero-proof Kava Oasis beveragelaunch

Deals & partnerships

Bluebird Botanicals Acquisition of a complementary brand with a loyal customer base and self-GRAS status on full spectrum products.

Validates M&A thesis by leveraging cbdMD's infrastructure, marketing engine, and NYSE American Listing to unlock value.

Risks & headwinds

Regulatory Headwinds (Section 781 of H.R. 5371) Near-term (November 2026)

Scheduled to take effect November 12, 2026

Mitigation:Advocating for legislative solutions (e.g., Senate Stock Gap Appropriations Proposal, Lawful Hemp Protection Act, Bipartisan Beverage Regulatory Parity Act); product reformulation, channel diversification.

State-level Regulatory Changes Ongoing

Impacted $150,000 of direct-to-consumer revenue in Q3 FY26

Mitigation:Managing through it, evaluating product reformulation, channel diversification.

Inventory Reserves Increase Q3 FY26 (one-time cost)

$187,000 increase in Q3 FY26

Mitigation:Proactive approach to changing regulatory environment, evaluating product reformulation.

Professional Fees for M&A/Regulatory Q3 FY26 (one-time cost)

$200,000 in Q3 FY26

Mitigation:These were deliberate investments, now implementing cost reduction program.

Gross Margin Compression Ongoing

54.7% in Q3 FY26 vs 61.5% in Q3 FY25

Mitigation:Evaluating pricing, product mix, manufacturing, and supply chain opportunities; implementing cost reduction program.

What to watch in Q4 FY26

Monthly cash cost savings realization

Q4 FY26
Current $100,000 to $150,000 target
Target Full realization of targeted monthly savings

Why it matters

Critical for improving profitability and adjusted EBITDA, and achieving cash flow break-even.

Beginning in the fourth fiscal quarter, we implemented a cost reduction program targeting $100,000 to $150,000 in monthly savings through payroll reductions, renegotiation of warehouse leases, negotiating exit vendor contracts, and we've identified additional supply chain savings, which we expect to begin to realize later this quarter.

Find out whether YCBD delivers this. Inve re-checks your case every morning.

Q&A highlights

Clarification on whether the $100k-$150k monthly savings are cash-based and the timing of their full realization, and the current cash flow break-even revenue run rate.

The savings are cash-based, mostly realized by end of August, with a small portion of lease savings bleeding into October. The cash flow break-even revenue run rate is now estimated in the low to mid $6 million per quarter.

“Yes, those numbers were cash related, Adam. [...] Correct, low six millions to mid six millions? That is how we are modeling this out right now.”

asked by Adam Waldo · answered by Ronan Kennedy

2 min read 5 chapters

Detailed narrative

Regulatory Environment and Advocacy

The company is navigating a dynamic regulatory landscape, particularly concerning Section 781 of H.R. 5371, which is set to narrow the federal definition of hemp and impose strict THC limits from November 12, 2026. Management is actively engaged in Washington D.C., supporting bipartisan bills like the Lawful Hemp Protection Act and the Bipartisan Beverage Regulatory Parity Act, which would regulate hemp-derived beverages similarly to alcohol.

The company believes a ban on full-spectrum hemp would drive consumers to unregulated black markets.

Strategic Investments and Cost Actions

cbdMD made deliberate investments in Q3 FY26, including legal and due diligence for M&A, new product development (Kava beverage), supply chain compliance, and clinical healthcare initiatives (GRAS for broad-spectrum CBD). These investments contributed to a wider operating loss. However, the company implemented a cost reduction program in Q4 FY26, targeting $100,000 to $150,000 in monthly cash savings through payroll reductions, renegotiating leases, and vendor contracts, aiming for improved EBITDA and contribution margins.

Oasis Brand Momentum and Diversification

The hemp-derived THC brand, Oasis, continues to accelerate, with distribution recently added in South Carolina and a new distribution partner in Texas, quadrupling store access. Depletions from distributors hit a record in July, up 35% over the Q3 average, with August on pace to more than double.

The company launched a zero-proof Kava Oasis beverage to capture shelf space with compliant products, mitigating regulatory uncertainty and building revenue visibility into 2027.

Bluebird Botanicals Integration and M&A Strategy

Bluebird Botanicals contributed over $500,000 in revenue in its first full quarter as part of cbdMD, validating the company's M&A thesis of leveraging infrastructure, marketing, and NYSE American Listing to unlock value. The company continues to evaluate disciplined acquisitions that diversify revenue, grow customer bases, and reduce regulatory exposure, focusing on short-term cash flow accretion.

Gross Margin Pressures and Mitigation

Gross margin declined to 54.7% in Q3 FY26, primarily due to a shift towards lower-margin wholesale sales and higher warehouse labor costs for product repacking due to changing state regulations. An additional $187,000 increase in inventory reserves was recorded. Management is evaluating pricing, product mix, manufacturing, and supply chain opportunities to improve gross margin and streamline responses to regulatory requirements.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.